Ardelyx, Inc. (ARDX): Product News News

ARDX – Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018.


Key Facts Surrounding This News Item


  • ARDX had a POWR Rating of D (Sell) coming into today.
  • ARDX was -6.25% below its 10-Day Moving Average coming into today.
  • ARDX was -3.23% below its 20-Day Moving Average coming into today.
  • ARDX was 2.96% above its 50-Day Moving Average coming into today.
  • ARDX was 4.02% above its 100-Day Moving Average coming into today.
  • ARDX was -39.85% below its 200-Day Moving Average coming into today.
  • ARDX had returned -61.97% year-to-date leading up to today’s news, versus a +15.53% return from the benchmark S&P 500 during the same period.

More Info About Ardelyx, Inc. (ARDX)


Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The company was founded in 2007 and is based in Fremont, California. View our full ARDX ticker page with ratings, news, and more.

ARDX at a Glance

ARDX Current POWR Rating™
Overall POWR Rating™
ARDX Current Price $5.80 3.33%
More ARDX Ratings, Data, and News

ARDX Price Reaction

The day of this event (Oct. 11, 2017)
ARDX Closing Price$5.40 0.00%
ARDX Volume2,779,500
897.39% from avg
Leading up to this event
ARDX 1-mo return5.26%
After this event
ARDX 1-day return30.77%
ARDX 3-day return15.63%
ARDX 5-day return0.00%

ARDX Price Chart



More Ardelyx, Inc. (ARDX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ARDX News
Page generated in 0.7593 seconds.